|Bid||84.53 x 400|
|Ask||84.55 x 200|
|Day's Range||82.91 - 84.76|
|52 Week Range||64.18 - 86.72|
|PE Ratio (TTM)||40.81|
|Earnings Date||Jul 25, 2017|
|Dividend & Yield||2.08 (2.51%)|
|1y Target Est||89.00|
Health care stocks got a lift Thursday after Senate Republicans rolled out their proposed bill to repeal Obamacare.
Lilly's new space will help foster and accelerate the discovery of medicines within the company's core therapeutic areas of immunology, diabetes, oncology and neurodegeneration, as well as the emerging area of pain. "This year we announced a commitment to invest $850 million in our U.S. operations based on our potential for growth and the company's long-standing investment in the U.S. market," said David A. Ricks, Lilly's chairman, president and chief executive officer.
On June 8, 2017, Eli Lilly (LLY) announced a strategic collaboration with KeyBioscience AG to focus on the development of dual amylin calcitonin receptor agonists (or DACRAs).